The rising numbers in the aging population will undoubtedly lead to a corresponding increase in percutaneous endovascular procedures to address their cardiovascular health issues. With a constant drive to develop innovative treatment methods to achieve improved treatment outcomes while reducing procedural- 
As the aging population continues to rise, there is a corresponding increase in the number of percutaneous radiologic and endovascular procedures to address their cardiovascular health issues. According to the United States Census Bureau, there will be 71 million people above the age of 65 years, and 19.5 million above the age of 80, ie, a Ͼ7% and 50% rise in 2030 compared with year 2000, respectively. Cardiovascular disease is the number one cause of death in the United States. Consequently, there is a constant drive to develop innovative methods and devices that enable interventionalists to achieve diagnostic or therapeutic goals while reducing procedural related risks and enhancing patient satisfaction, and performing outpatient procedures. One area of percutaneous vascular interventions, which has received intense focus in the past decade relates to technologies to achieve rapid and effective control of femoral arterial access, which is traditionally accomplished by manual compression. These arterial closure devices (ACD) have been shown to reduce time of hemostasis, enable early patient ambulation, reduce hospitalization staff utilization, and improve patient outcome. 1 However, these ACD have their shortcomings and the interventionalists need to know about these devices, how they work, and their potential complications. Minor and major complications have been reported from 1.5% to 9% 2, 3 with up to 40% requiring surgical repair. Table I lists some of the complications reported with ACD use. First introduced in conjunction with the Seldinger percutaneous puncture technique, manual compression (MC) has been regarded as the standard method to achieve hemostasis following percutaneous procedures for nearly five decades. Manual compression is performed with sustained pressure over the puncture site for 15 to 20 minutes followed by bed rest for an additional 6 hours. While this technique is sufficient in achieving groin hemostasis in the majority of patients undergoing percutaneous procedures, manual compression may not be effective in providing sustainable hemostatic pressure in obese patients. Additionally, patients with certain medical comorbidities related to lumbar or pelvis ailments may encounter difficulty with prolonged immobilization. With increased utilization of various anticoagulation regimens during percutaneous interventions, including antiplatelet glycoprotein IIb/IIIa inhibitors, groin-bleeding complications with MC have similarly risen sharply. 4, 5 The shortcomings related to manual compression coupled with efforts to improve post-catheterization hemostasis have led researchers to develop a variety of vascular closure devices in the past decade. The primary advantage attributed to VCD is shortened duration to achieve hemostasis and avoidance of prolonged immobilization so that earlier ambulation and outpatient discharge can be achieved following percutaneous procedures.
There are no large randomized clinical trials comparing ACD vs manual compression (MC), but two meta-analyses showed marginal or no benefit of ACD over MC. 1, 2 However, there was significant heterogeneity of the studies reviewed in these meta-analyses in the setting with which the ACD were used, as well as the patients and the operator. In addition, most MC was done after reversal of activated clotting time (ACT), while ACD were deployed regardless of anticoagulation status. Strategies to reduce vascular complications with ACD have been effective and showed promising reduction in complication rates. 6, 7 Also, new generation devices have been revised and improved with fewer complications reported. 3, 6 This article provides an overview of the technologies available as an alternative to MC to achieve hemostasis after percutaneous catheterization procedures. Clinical data to support their utility and compare them with MC, as well as complications related to these closure devices are also discussed.
OVERVIEW OF VASCULAR CLOSURE DEVICES
Significant advances have occurred in the past decades in vascular closure technologies leading to several important design features that merit consideration when choosing a vascular closure device. There is no ideal device; each one has its own inherent problems. Despite the advances made to improve these ACD, their use did not increase rapidly, some reporting only one-third utilizing it after a diagnostic catheterization. 8 This is due to lack of superiority of ACD over MC, concern for cost, and lack of reimbursement.
Ideally, a closure device should be simple to use without cumbersome deployment mechanism and should be safe. The activation of the device closure mechanism should be reliable and consistent with low complication rates comparable to traditional manual compression methods. The utilization of a closure device should not incite significant inflammatory reaction in the surrounding tissue. The latter feature allows procedural safety if postinterventional repeat puncture or surgical access is necessary. Lastly, an ideal device must be cost effective. Cost-effectiveness is a tough issue to decipher; it depends not only on cost but also on reimbursement, on the reduction of cost related to complications as well as comparison to what mechanism of external compression is used as MC. Using a C-clamp or other similar device is cheaper than a staffing personal putting external pressure. There are no CPT codes for reimbursement; the codes available for ACD are codes used by physicians and institutions to report or track their use. Cost reduction driven by reduction in vascular complications is small especially in patients undergoing diagnostic procedures where the complication rate is lower. 3, 8 All these different factors make the cost-effectiveness calculation very complex and difficult. A small randomized trial comparing ACD with MC showed a modest reduction in hospital stay of ϳ70 euro per patient. 9 This cost saving could be potentially lost if a fem-stop or similar device was used, which is cheaper than a nurse or health personnel applying MC.
Based on the mechanism and technology utilized by these devices to achieve hemostasis, they can be divided into three broad categories. They include (1) collagenbased technology, (2) suture-mediated technology, and (3) staple or clip-based technology. Commonly used vascular closure devices based on these three mechanisms are listed in Table II .
COLLAGEN-BASED VASCULAR DEVICES
Devices that utilize collagen to achieve hemostasis are primarily based on bovine biodegradable products to augment thrombus formation. The hemostatic formation of collagen-based closure devices is based on two biochemical reactions. The collagen plug is deployed outside the vessel wall on the arteriotomy site. This exogenous collagen material forms an extracellular lattice, which triggers a hemostatic cascade by promoting platelet aggregation, adherence, and activation. 10 Secondly, upon contact with blood, the collagen expands its physical mass resulting in mechanical occlusion of the vessel puncture site and tissue tract.
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Because of the degradable nature of these proteinaceous bioproducts , the resorption of these collagens may lead to varying degrees of inflammatory processes in the surrounding soft tissue. 12 Repeat puncture or surgical exploration of the same artery may lead to increased difficulty due to subcutaneous inflammatory tissue reaction. In vivo studies have shown that collagen plugs are resorbed within 4 weeks, which subsequently leads to the recommendation that repeat access or surgical exploration of the same vessel should not be performed for 4 weeks following the deployment of the collagen-based devices. 4, 10, 13 Common examples of these collagen-based closure devices include AngioSeal (St Jude Medical, St Paul, Minn), VasoSeal (St Jude Medical), and Duett (Vascular Solutions, Minneapolis, Minn).
Angio-Seal. The Angio-Seal (St Jude Medical) received its initial approval from the Food and Drug Administration (FDA) in 1996. With more than 7 million devices distributed worldwide since its introduction, Angio-Seal is one of the most widely used arterial closure devices. This device went through multiple revisions, and the current one is very user friendly. This is a bioabsorbable collagen closure device, which consists of an absorbable, intraarterial anchor, a small bovine collagen plug, and an absorbable traction suture (Fig 1) . 14, 15 At the completion of the percutaneous angiography, the anchor and collagen plug are inserted into the artery through a specially designed sheath and then pulled up snugly against the arterial wall to seal the puncture site. The intra-arterial anchor is a T-shaped material composed of copolymers of polylactic and polyglycolic acids. When deployed, the combination of anchor, collagen plug, and absorbable suture effectively sandwiches the puncture site between the anchor and the extravascular collagen plug to seal the arterial puncture site. The Angio-Seal is available in a 6F or 8F system. Femoral arteriography is recommended prior to device deployment as calcified vessel walls may preclude safe device anchor deployment and device activation. Additionally, angiographic confirmation of the puncture site is necessary, as the device should not be deployed in the external iliac artery, superficial femoral artery, or profunda femoris artery. Another consideration to avoid the use of this device is in peripheral vascular disease patients and vessels less than 5 mm in diameter. The intraluminal anchor and collagen plug are absorbed within 30 days. Therefore, vessels should not be accessed for 1 month following placement of an Angio-Seal device. If reaccess is needed, then it can be done 1 cm above the previous access site. 16 Similarly, if surgical exploration or femoral revascularization is a possibility following arteriography, this type of bioabsorbable collagen device should not be utilized. If device deployment fails, hemostasis can still be achieved with manual compression. Infrequent complications such as acute femoral artery thrombosis can occur due to inadvertent plug deployment within the intraluminal space, which will necessitate urgent surgical exploration and plug removal (Fig 2) .
VasoSeal. The VasoSeal (St Jude Medical, St Paul, Minn), is a closure device utilizing a purified bovine collagenbased plug to achieve hemostasis at the arterial punctured site (Fig 3) . Since the first generation of the VasoSeal device was approved by the FDA in 1995, there have been a total of four different platforms of VasoSeal which include (1) VasoSeal Vascular Hemostasis Device (VHD), (2) VasoSeal ES (Extravascular Security), (3) VasoSeal Low Profile, and (4) VasoSeal Elite. 17, 18 These various platforms are intended to be used for varying diameters of the arterial punctured site. Both VasoSeal Elite and ES utilize a temporary J-shaped locator segment, which is deployed so the collagen plug is deposited on the outer surface of the vessel wall along the puncture tract. The main difference between the Angio-Seal and VasoSeal is that the latter device does not possess any intraluminal components, while an AngioSeal deploys an intraluminal plug to achieve hemostasis. The VasoSeal device may be used with the maximum sheath size of 8F introducer sheath. Following the VasoSeal device deployment, patients only need to remain in bed rest for 1 hour before they can be ambulatory. Repeat arterial puncture can be performed after 6 weeks of deployment of the VasoSeal device. Because this device deploys an extraluminal collagen plug, femoral artery calcification or peripheral artery disease is not considered a contraindication for VasoSeal deployment. Also, there is no need for a femoral angiogram prior to deployment. However, the VasoSeal It is advanced until blood flows out through the exit hole in the dilator as shown. It is then withdrawn until blood flow ceases and is advanced until the blood flow restarts. B, Locator and guidewire are removed. The Angio-Seal is inserted fully into the sheath with two arrows on the sheath and device assembly meeting. The anchor will then be released beyond the sheath tip. The barrel of the device is retracted with a double "click," and the whole assembly is then withdrawn. The anchor will be fixed against the inside of the vessel by gentle traction. A tamper becomes visible on the suture as the sheath is removed. C, Once fully visible, the tamper is advanced forward to tie a knot over the collagen plug, which becomes compressed against the puncture site. The suture is then cut above the tamper, and the tamper is removed.
Fig 2.
Groin exploration after a young female complained of right leg claudication subsequent to intracranial aneurysm embolization. Angio-Seal was used for arteriotomy closure, which resulted in inadvertent plug deployment within the intraluminal space. The plug was removed and the femoral artery repaired with bovine patch angioplasty. device is contraindicated in obese patients, due to device length limitations.
Because the collagen plug is deployed in the extraluminal space, patients frequently experience an irritated skin lump due in part to the inflammatory reaction caused by the collagen plug resorption. The manufacturer has addressed this issue by reducing the amount of bovine collagen inserted in later versions of the device. In the event of device deployment failure, hemostasis of the arterial puncture can be remedied with the conventional manual compression. Infrequent complications such as acute femoral artery thrombosis can occur due to inadvertent plug deployment within the intraluminal space, which will necessitate urgent surgical thrombectomy and plug removal.
Duett device. The Duett sealing device (Vascular Solutions) combines the procoagulant effect of thrombin with the platelet activation of collagen plus a 3F balloon catheter. This closure technology is based on an extraluminally placed collagen-based hemostatic component. The balloon catheter is first deployed through any existing 5F to 9F vascular sheath. The catheter is subsequently delivered into the artery, which is followed by the inflation of a 3 mm ϫ 7 mm balloon (Fig 4) . The inflated balloon is then withdrawn anteriorly against the intraluminal surface of the arteriotomy to create a temporary puncture site hemostasis. This is followed by the injection of procoagulant agents into the sidearm of the sheath as it is slowly withdrawn. Continual infusion of the procoagulant while the sheath is withdrawn triggers an accelerated clotting cascade and platelet activation to close the subcutaneous tract. This cascade is characterized by the conversion of fibrinogen into fibrin by the action of thrombin in the presence of collagen resulting in accelerated coagulation reaction. The balloon is lastly deflated and withdrawn completely from the puncture site. This is a low profile catheter and does not disrupt the plug upon removal. Additional manual compression for 3 minutes is necessary to achieve hemostasis. 19 Similar to the VasoSeal device, there is no intraluminal anchor. The Duett device has been shown to be effective in achieving satisfactory hemostasis and early ambulation compared with manual compression. [19] [20] [21] Vessels, which have been treated with the Duett closure device, can undergo repeated puncture immediately for angiography and cause minimal local inflammation. Potential accidental injection of collagen into intraluminal space can occur due to suboptimal balloon inflation. This could happen in peripheral artery disease patients where the balloon gets stuck to the posterior plaque and does not seal the arteriotomy from the thrombin injection. Consequently, one potential complication of the Duett device is that of inadvertent infusion A, The arteriotomy locator is inserted through an introducer into the sheath. B, With occlusive pressure above the arteriotomy, the sheath is removed, and the locator is retracted until the J-segment is deployed. The entire segment is retracted until resistance is felt. C, The white tissue dilator is advanced, followed by the blue sheath dilator, until a marker indicates the tip is at the arteriotomy site. D, Locator and tissue dilator are removed, leaving only the outer sheath. The collagen cartridge is inserted into the sheath and the plunger is advanced initially; then the sheath is retracted to fully deploy the collagen plug. The sheath is removed, and pressure is applied to the skin until hemostasis is achieved.
of the procoagulant solution into the artery resulting in acute arterial thrombosis. 13 This complication has been treated with either thrombolysis or thrombectomy.
SUTURE-BASED VASCULAR CLOSURE DEVICES
These devices achieve arterial hemostasis by deploying sutures, which are tied to form a surgical knot to close the arteriotomy. The knot is tied by a built-in mechanism within the closure device, but can also be tied manually if necessary. Because there is no proteinaceous biomaterial left behind in the puncture tract, there is no bioresorption or inflammatory soft tissue reaction associated with this closure technology. Consequently, repeat arterial access or immediate surgical exploration of the same artery can be performed safely. Common examples of these suture-based closure devices include Perclose (Abbott Vascular Devices, Redwood City, Calif), X-Site (Datascope, Montvale, NJ), and SuperStitch (Sutura, Fountain Valley, Calif).
A list of these suture-based closure devices is provided in Table II .
Perclose device. The Perclose device (Abbott Vascular Devices) was the first suture mediated closure system approved by the FDA in 1997. There are various Perclose platforms including (1) the ProGlide, (2) Perclose A-T, (3) Closer S, and (4) Prostar XL, which can deploy single or double nonabsorbable sutures and are intended for various introducer sheath sizes ranging from 6F to 10F. These devices differ in the sheath size, suture type, and suture deployment. To deploy the Perclose device, it is first advanced into the artery over a guidewire. After proper positioning, a braided 3-0 polyester suture is deployed, and the device is removed after the knot has been tightened down around the puncture site (Fig 5) . The Prostar XL device was the earliest version, which utilizes a series of complex mechanisms that involve the delivery of either 2 or 4 needles from inside of the artery. These suture-attached needles are punctured across the artery, which are engaged by the barrel of the delivery system. Once engaged in the arterial wall, the sutures are manually tied in a conventional surgical slipknot, which is pushed down toward the surface of the arteriotomy to achieve suture-mediated closure. 4, 22 These devices were not popular because the operator needs to form and push down the knot. The newer devices have a pretied knot. The recent platforms of Perclose devices, including the ProGlide, Perclose A-T, and Closer, are based on a different design in which needles are deployed from outside the vessel and the device captures the suture immediately. The Closer device requires the operator to tie the suture manually, while the Perclose A-T device already has a pretied knot. The Closer and A-T device may be utilized to achieve hemostasis following the use of 5F to 8F sheaths. Similar to the Angio-Seal system, the Perclose device provides arterial anchoring to achieve hemostasis, which is a beneficial feature in patients who receive anticoagulants. Similar to the Duett device, the Perclose system can be applied in the same artery immediately following its deployment. Unlike all other collagen-based closure systems, the closure mechanism in the Perclose device, which is based on a monofilament polypropylene suture, represents a permanent foreign material in the extravascular space.
X-press device. The X-press device (X-Site) was a recently introduced suture-mediated closure device. This device consists of three mechanical components to achieve hemostasis, which includes an over-the-wire device, a suture attached to two needles, and a knot pusher, which also functions as a suture cutter. Unlike the Perclose device, the X-Site system contains no intra-arterial component for suture-mediated closure. Deployment of this device involves sequential engagement of the first needle with a subsequent 180°twist, which is followed by the deployment of the second needle. The sutured knot is then tied down manually or by using a knot tier. Unlike the Perclose device, which has a wide range of applicability of various A, The 3F catheter is advanced through the working sheath which has a balloon at its tip. The balloon is inflated with a syringe and is retracted until it engages the arterial wall at the puncture site. B, Procoagulant mixture is then delivered through the sheath side arm directly to the puncture site and continued as the sheath is retracted. The entire subcutaneous tract is filled and thrombosed. C, The balloon is deflated, and the catheter and sheath are removed. The skin is compressed for 2 to 5 minutes.
introducer sheath sizes, the X-Site is approved for closure in sheaths up to 6F in size.
SuperStitch device. The SuperStitch device (Sutura) is also a recently introduced suture-mediated closure device, which utilizes nonabsorbable monofilament polypropylene sutures to close the arterial puncture site. The device can be deployed through a conventional access sheath and is advanced without wire guidance. To deploy the sutures, three buttons on the body of the device are activated in a sequential fashion to initiate the suture-mediated closure mechanism (Fig 6) . A unique feature of this device is that it can be used to close arterial punctures even in an antegrade approach. Because of its relatively short history in commercial applications, there is no large series of clinical data comparing this device with other suture-based closure devices.
METAL CLIP OR DISC-BASED VASCULAR CLOSURE DEVICE
Devices, which utilize metal clip-based technology, deploy either metal staple or clip that penetrates the vessel wall to achieve hemostasis. Upon deployment, the metal clip or staple remains in situ over the vessel wall and forms a geometric configuration that approximates adventitial vessel layers to close the arterial hole. Unlike the collagenbased devices, these metallic clips or staples do not undergo a bioresorption reaction, which therefore does not trigger significant soft tissue inflammatory response. Repeat puncture or surgical exploration of the artery can be done safely. Common examples of these closure devices include Angiolink EVS Vascular Closure System (Medtronic) and StarClose (Abbott Vascular) . A list of these clip-based closure devices is provided in Table II .
StarClose closure system. The StarClose device (Abbott Vascular, Redwood City, Calif) features a 4-mmdiameter, flexible nitinol clip, which is designed to close femoral arteriotomies created by sheaths up to 6F in size. The system consists of an introducer sheath, dilator, guidewire, and a clip applier. Activation of the locator button deploys small flexible wings that form the locator. An implantable nitinol clip is positioned in the clip applier. When the device is activated, the nitinol staple is engaged in the adventitial layer of the vessel whereby its tines grasp the edges of arteriotomy and draw them together to close the puncture hole (Fig 7) . In contrast to collagen-based devices, the nitinol used in the StarClose device is a widely utilized metallic material commonly used in intra-arterial stent or stent graft devices, which has a low profile in bioreactivity in inducing inflammatory soft tissue reaction.
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Angiolink EVS vascular closure system. The Angiolink EVS Vascular Closure System (Medtronic, Santa Rosa, Calif) deploys an extraluminal titanium staple to achieve vascular hemostasis without penetrating all three layers of an artery. Prior to the staple deployment, a series of vessel stabilizers align the arteriotomy hole into a linear configuration. A titanium staple is deployed at the adventitial layer, which approximates the puncture site to achieve hemostasis. Similar to the nitinol material of the StarClose device, the inert properties of titanium in the Angiolink device induces minimal biologic response or inflammatory tissue reaction in comparison to collagen-based devices. 4, 12 Boomerang closure device. The Boomerang closure device system (Cardiva Medical, Mountain View, Calif) utilizes an 18-G conformable nitinol-based wire with a temporary nitinol braided mesh disc on a tether which is deployed inside the artery to achieve hemostasis. This device received an FDA approval in October 2004. It creates a site-specific compression between the arteriotomy and tissue tract, resulting in targeted internal compression. The hemostatic mechanism is based on the recoiling of the arteriotomy site, which is analogous to the "boomerang" effect (Fig 8) . After a few minutes of device deployment, the nitinol mesh disc and wire are then removed, thus leaving no foreign body in either intraluminal or extraluminal space. This is then followed with 5 to 7 minutes of manual compression over the remaining puncture site to achieve complete hemostasis. The Boomerang device is designed to close femoral arteriotomy created by sheaths Sutures are deployed around the arteriotomy and are pulled from the device outside the skin. C, The pre-tied knot is pushed down using the knot pusher that comes with the device. Once hemostasis is achieved, the suture is cut using a knot cutter. The final suture lies securely around the arteriotomy to achieve hemostasis.
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December 2010 from 4F to 10F in size. A recent study cited an impressive success rate of 99% in achieving complete hemostasis with an average time of 82 minutes from the end of device application to ambulation. 23 However, the need for manual compression following the device application represents a potential drawback of this particular device.
APPLICATION OF PERCLOSE DEVICE IN ENDOVASCULAR STENT GRAFT PROCEDURE
While all available closure devices are effective in achieving hemostasis for the conventional interventional vascular procedure using either 5F or 6F introducer sheaths, the Perclose Prostar device utilizes a unique suture-mediated technology, which enables its application in percutaneous endovascular aortic stent graft procedures where large introducer sheaths up to 20F or 24F are routinely used. It is noteworthy that Prostar XL is approved for arteriotomy closure created by a 10F sheath size. Several studies have reported various offlabel application of a "Preclose" technique or double deployment of either Prostar or Preclose devices to achieve hemostasis following percutaneous interventional procedures of sheath up to 24F in size. [24] [25] [26] [27] This "Preclose" technique requires placement of two Perclose devices 90°to each other at the beginning of the procedure leaving the knots untied. 24, 25 Alternatively, a single Prostar XL can be used for large introducer sheath applications. The puncture site is then dilated to the appropriate size, and the sutures are ultimately tied once the endovascular stent-graft procedure is completed. 27, 28 This technique has been described in percutaneous deployment of endovascular aortic grafts, peripheral covered stents, and intra-aortic balloon pumps. 27, 29 A brief description of this percutaneous technique using a single Prostar XL device for endovascular aortic stent graft procedures is provided below.
To perform a percutaneous endovascular aortic repair utilizing a Prostar XL device, it is important to first assess the femoral artery using an ultrasound to determine its diameter and associated vessel calcification. Only femoral arteries greater than 7 mm in diameter without circumferential calcification should be considered for this percutaneous approach. Fluoroscopic imaging is used to identify the femoral head and an Ultrasound-guidance access of the common femoral artery is obtained percutaneously in which a 6F sheath is inserted. A 1-cm incision is created next around the sheath, with blunt dissection of the subcutaneous tissue. The sheath is removed over the wire and a 10-F Prostar XL device is advanced into the common femoral artery with the tip placed in the distal aorta (Fig 9) . When pulsatile blood flow is noted through the marker lumen, which indicates the sutures and needles are within the vessel lumen, all four needles and sutures are deployed by aligning the barrel and withdrawing the ring (Fig 9) . It is important to maintain the proper amount of tension on the shaft to avoid compression of the artery during deployment of the needles, which also ensures that the sutures are placed adjacent to the arteriotomy and only in the anterior wall of the artery. The two sutures which are colored white and green are next separated from the Prostar XL and placed under towels across the groin (Fig 9) . The device is removed over the wire, and progressive dilations are performed to allow placement of the appropriate-sized sheath for endograft deployment. The procedure can be repeated on the opposite groin for the contralateral limb. The operator has to form the knot in each of the two Prostar XL sutures using a sliding-knot technique. One end of the suture is the rail end, which is used to pull the knot all the way down to the arteriotomy site. The other end, the non-rail end, is used to lock the knot. A wire is placed in the monorail side port on the sheath of the device to maintain arterial access in case of device failure. When the large introducer sheath is withdrawn, both suture rails are pulled with tension to slide the knots downward to the femoral arterial wall (Fig 10) . If there is no bleeding, the wire is removed and a knot pusher (Abbott Vascular Devices, Abbott Park, Ill) is used to advance the sliding knots to the vessel wall (Fig 10) . Lastly, the non-rail end of the suture is pulled to lock the knot in place, and the sutures are cut close to the arterial wall. Standard groin dressings are lastly applied in bilateral groins. Clinical series using this Prostar device or double Perclose devices have been reported with remarkable success rates of 88% to 96% in achieving hemostasis following percutaneous procedures with sheaths greater than 16F in size. 24, 25, [27] [28] [29] [30] All authors from these clinical series uniformly underscored a clear learning curve in which early procedure failure is common. With proper selection of the femoral artery and increased operator's experience, endovascular aortic procedures can be achieved with the percutaneous approach using the Preclose device with high success rates. In one study looking at early and midterm outcomes of femoral arteries after PEVAR, at a mean follow-up of 11.6 months, only 3 (1.92%) patients required repair of their femoral artery. 31 The overall early technical success was 94.4%, but when looking at different subsets of sheath sizes, the larger sheaths (Ͼ18F) had the lowest technical success at 92.8%. 31 In another study comparing percutaneous access with femoral cut down for EVAR, the percutaneous group had lower overall complications as well as the subset of patients with calcified vessels and obese patients.
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CLINICAL EXPERIENCE WITH VASCULAR CLOSURE DEVICES
There is no large randomized study comparing the different ACD to each other and/or to MC. In one single institution randomized study involving 705 patients randomized to three ACD (Angio-Seal, VasoSeal, and Duett) in the setting of diagnostic and percutaneous coronary intervention (PCI), which requires a larger sheath, all three devices had a high rate of technical success with surgical intervention rate of 1%. 33 Angio-Seal provided earlier time to ambulation compared with the other two devices. All three devices were considered safe; however, the vasoseal device had a slightly higher rate of complication compared with the other two in the PCI group. 33 In another larger series evaluating ACD use in the setting of PCI and anticoagulation in more than 4500 patients, ACD had a similar or lower complication rate than MC. 34 The two devices used were Angio-Seal and Perclose. Deployment of the StarClose closure device. A, The sheath is introduced first over a wire followed by the StarClose device that is inserted into the sheath after wire removal. The vessel locator button is depressed. The device is pulled out until resistance is felt. The advancement of the thumb advancer completes the splitting of the sheath. The device is raised to an angle of slightly less than 90°. B, The clip is deployed to catch adventitia for hemostasis and the device is retracted.
In one meta-analysis reviewing 30 sources showed only a marginal benefit of ACD over MC at an increased risk of groin hematoma and pseudoaneurysm. 2 As mentioned earlier, this meta-analysis did not look at the heterogeneity of the studies, and included reports on the early use of ACD with lack of operator comfort. Another meta-analysis looked at comparing ACD (Angio-Seal, Perclose, and VasoSeal) to MC in the setting of diagnostic angiogram and PCI in over 37,000 patients. It showed that in the setting of diagnostic angiogram, access-site related compli Fig 8. Deployment of the Boomerang closure device. A, The wire is inserted through an existing sheath. B, The tip is deployed and opens into a conformable disc. C, The sheath is removed; this tamponades the arteriotomy. D, The device is pulled after collapsing the disc, and light manual compression is applied until hemostasis is achieved.
Fig 9.
Using a Perclose Prostar device in endovascular aortic stent-grafting procedure. A, Access to the common femoral artery is confirmed angiographically. B, The 10F Prostar XL is advanced over the wire. This should be done under fluoroscopic guidance since the device is long and the tip ends up the aortic bifurcation. C, When pulsatile flow is seen, this indicates that the device with its sutures is intraluminal. The needles are deployed while maintaining gentle forward pressure to keep the device intraluminal. D, T sutures are deployed around the arteriotomy and are checked for intraluminal position by applying a gentle pull. This means the sutures did catch the arterial wall. There is a green and a white suture, which are separated and tagged until the end of the case. Prior to removing the device (white tip device in figure B) , a wire is reintroduced to place a sheath to proceed with PEVAR.
JOURNAL OF VASCULAR SURGERY Volume 52, Number 6 cations were similar for all ACD compared with MC. However, in the PCI group, VasoSeal had a higher complication rate. The overall analysis favored MC over ACD. 3 As one of the most widely used closure devices, the Angio-Seal device has been reported in the literature with an abundance of clinical experience. [35] [36] [37] [38] [39] [40] [41] All available studies cited a high clinical success rate in achieving hemostasis which ranged from 92% to 98%. [35] [36] [37] [38] [39] [40] [41] Device failure is relatively uncommon in the clinical series with high procedural volumes, which ranged from 1% to 3%. [35] [36] [37] [38] [39] [40] [41] Nonetheless, simple application of manual compression would almost uniformly achieve hemostasis even in the event of device failure. 4, 35, 40, 41 Common modes of device failure are related to the inability to advance the locator sheath in a scarred groin or improper anchor positioning which ultimately resulted in suboptimal application of the collagen plug. 14, 18, 40 Several comparative studies analyzing Angio-Seal vs manual compression reported shorter time to hemostasis and ambulation in patients treated with the Angio-Seal device. [42] [43] [44] A randomized trial comparing Angio-Seal with MC showed reduced time to hemostasis and earlier ambulation in the Angio-Seal group despite anticoagulation as well as reduced complication. 45 In another randomized study comparing Angio-Seal to fem-stop device, the early benefit of Angio-Seal in the first 2 hours with reduced local groin complication was lost at 24 hours.
However, the fem-stop group received external compression only when the ACT was Ͻ100; meanwhile the AngioSeal was deployed regardless of anticoagulation status. 46 Inadvertent deployment of an intraluminal collagen plug can lead to femoral artery occlusion, which is a major complication with a reported incidence ranging from 0.8% to 3.6%. [35] [36] [37] [38] [39] [40] [41] 43, 44 One can reduce this potential complication by avoiding placement of the Angio-Seal device in arteries less than 5 mm in diameter or in arteries with significant circumferential calcification or thrombus which may compromise the flow lumen. As with all percutaneous closure devices, the deployment of the Angio-Seal device in the common femoral artery can ensure the highest likelihood of clinical success.
The VasoSeal device has similarly endured a high degree of clinical scrutiny in the literature. Numerous clinical series have reported high technical success rates ranging from 90% to 100%. 4, 17, 18, 33, 38, 47 In patients who received systemic anticoagulation, this device remained efficacious in achieving hemostasis following percutaneous interventions. 17, 47, 48 Several comparative studies between the VasoSeal device and manual compression demonstrated no differences in the rate of femoral artery pseudoaneurysm or hematoma formation. 4, 17, 18, 38, 47, 48 In the early 1990s, multiple randomized studies favored MC over VasoSeal use in patients undergoing PCI. 49, 50 However, other reports 9) . A, When an endovascular aortic procedure is completed, the pre-deployed sutures of a Perclose Prostar device are ready for knot tying. The white structure in these figures is the sheath. Both sutures are pulled upward to create an upward suture tension, making sure the same colored sutures are together. The operator has to form a knot, and one end, which locks the knot, called the non-rail end, is left alone till the knot is pushed all the way down to the arteriotomy site. B, Endovascular sheath is removed and both suture rails (white and green) are pulled gently. This slides the knot down to the femoral arterial wall. C, A knot pusher is used when the sheath is removed. If hemostasis is satisfactory, the non-rail suture is pulled to secure the knot on both sutures. D, Once the hemostasis is achieved, extra sutures are cut.
published in the late 1990s showed the benefit of VasoSeal over MC. 51, 52 This difference was the result of the multiple revisions the VasoSeal received. Also, this device requires a large subcutaneous tract for device deployment. If the device fails, this could lead to an increase in local vascular complications.
Early versions of the VasoSeal device were associated with an increased incidence of groin infection. 17, 33, 47, 48 However, subsequent studies based on more recent device platforms showed no evidence of increased infectious complications. 17, 33, 47, 48 Similar to the Angio-Seal device, which deploys an extraluminal collagen plug, femoral artery occlusion due to inadvertent intraluminal collagen plug deployment with the VasoSeal device has been reported. 18, 53 The clinical efficacy of the Duett device has been assessed in several studies, which uniformly noted high technical success rates which ranged from 93% to 100%. 19, [54] [55] [56] [57] Clinical studies also demonstrated a faster time to hemostasis and ambulation in patients treated with the Duett device compared with those treated with manual compression. 19, [54] [55] [56] [57] The efficacy of the Duett device was similarly remarkable regardless of whether angiographic procedures were performed for diagnostic or therapeutic intent. 12, 19, 20, [54] [55] [56] [57] Similar treatment success was also reported in patients who received full anticoagulation. 21, 54 Other studies noted no differences in terms of complications, including femoral artery pseudoaneurysm, hematoma, or groin infection, between patients treated with the Duett device vs those treated with manual compression. 19, 21 In the event of an unusual complication of a femoral artery thrombosis following the deployment of the Duett device, successful flow restoration has been reported using catheter-directed thrombolytic therapy. 21, 55 As the first approved device using a suture-mediated technology, the Perclose device was viewed by many as a technology utilizing many cumbersome steps for suture deployment and knot creation. While several clinical studies reported device success rates ranging from 90% to 100% which is similar to other devices. 22, 48, [58] [59] [60] [61] [62] Device failure, while uncommon, has been attributed to suture breakage or failure to create a secured knot. If the Perclose device fails, MC can achieve hemostasis. The device allows for wire re-introduction while maintaining intraluminal access if it fails to deploy. Experience with the device and the decision whether to hold MC or reintroduce the wire requires good clinical judgment especially in patients with peripheral vascular disease. 63 Comparative studies between the Perclose device vs manual compression noted a faster time to achieve hemostasis and ambulation when using the Perclose device. 22, 48, [58] [59] [60] [61] [62] There are multiple small randomized studies comparing Perclose to MC in the setting of diagnostic angiography, PCI, and both. The results are mixed; some favor Perclose with fewer complications 41, 52, 64, 65 and others favor MC. 18, 53, [66] [67] [68] The variety of these results is related to the evolution of this device; the newer devices are easier to use with a pre-tied knot. Similar to other devices, this device can achieve a high degree of success even in patients who receive anticoagulation. 22, 48, [58] [59] [60] [61] [62] An unusual complication of femoral arteritis has been reported with early platform of Perclose device which used a braided suture. 48, 69, 70 The introduction of the ProGlide model, which incorporated an improved suture trimming mechanism and replaced braided suture with monofilament polypropylene suture, has reduced the incidence of device failure and lowered the risk of infectious complication. 48, 69, 70 The StarClose device is the most commonly used device utilizing a metal-based staple technology. Several studies, which compared the efficacy of this device with manual compression, found that the StarClose device was associated with significantly reduced time to hemostasis and ambulation. 35, [71] [72] [73] [74] [75] A different study, which compared patients treated with StarClose vs Angio-Seal, found that both devices had similar efficacy and safety profile in achieving groin hemostasis. 76 However, patients who received the StarClose device were more likely to require post-deployment manual compression than those treated with Angio-Seal device. 76 We concur with this finding, and, from personal experience, noted that the nitinol ring was frequently deployed in the subcutaneous tissue rather than the adventitia upon femoral exploration during subsequent revascularizations. The nitinol ring misplacement narrowed or compressed the tract along with external compression hemostasis could still be achieved.
The use of ACD and their safety is still debatable. However, like any new technology introduced, it takes time for the operator to gain experience as well as make the ACD safer and easier to use. Recent data show that the newer ACD devices as well as operator experience are associated with less complications. 6, 77, 78 Also ACD devices could be safely used in patients with peripheral vascular disease with no alteration of their ankle-brachial indices. 37 Calculating cost-effectiveness is multifactorial, and it is not known if ACD use is associated with reduced cost. But it is intuitive that ACD are cost-effective if they are associated with less vascular complications. Multiple studies have shown that ACD are associated with decreased hospital length of stay compared with MC. 9, 16, 78 The biggest benefit would be if these devices could convert therapeutic interventions to an outpatient procedure. This might be eventually answered when the use of ACD is reimbursed. This will provide an incentive for a large randomized study evaluating their safety and cost-effectiveness compared with MC.
CONCLUSION
All available current devices have been shown to shorten time to hemostasis and ambulation compared with manual compression. These benefits could translate to a potential decrease in hospital stay and early discharge following percutaneous endovascular procedures. Despite the clinical efficacy of available closure devices, interventionalists must be cognizant that all closure devices are associated with a definite learning curve. There is no one single device that is ideally suited for all patients. Familiarity with different devices will be helpful in using certain devices in differ-ent clinical situations. For instance, the need for immediate percutaneous access or operative groin intervention may favor the use of a closure device, which does not utilize certain collagen-based plugs as the risk of soft tissue inflammation and operative scarring may be significant.
The current available arterial closure devices have made this technology an essential component of endovascular clinical practice. Interventionalists should consider all patients undergoing percutaneous arterial procedure as candidates for closure device application. Institutions should have their own algorithm for ACD use. They should examine the safety and cost as well as technical success and come up with an algorithm as to whether to use ACD or MC, while awaiting a large randomized study that will put these concerns to rest. 
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